These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29129600)

  • 21. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigational drugs in clinical trials for Hidradenitis Suppurativa.
    Theut Riis P; Thorlacius LR; Jemec GB
    Expert Opin Investig Drugs; 2018 Jan; 27(1):43-53. PubMed ID: 29188733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
    van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
    Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
    Ingram JR; Burton T
    Br J Dermatol; 2017 Feb; 176(2):281-282. PubMed ID: 28244073
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of patients with hidradenitis suppurativa.
    Martorell A; Caballero A; González Lama Y; Jiménez-Gallo D; Lázaro Serrano M; Miranda J; Pascual JC; Salgado-Boquete L; Marín-Jiménez I
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():32-42. PubMed ID: 28081768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
    Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
    J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
    Bechara FG; Podda M; Prens EP; Horváth B; Giamarellos-Bourboulis EJ; Alavi A; Szepietowski JC; Kirby J; Geng Z; Jean C; Jemec GBE; Zouboulis CC
    JAMA Surg; 2021 Nov; 156(11):1001-1009. PubMed ID: 34406349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience.
    Chiricozzi A; Giovanardi G; Garcovich S; Malvaso D; Caldarola G; Fossati B; Guerriero C; De Simone C; Peris K
    Acta Derm Venereol; 2020 Jun; 100(13):adv00172. PubMed ID: 32421198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moderate to severe hidradenitis suppurativa treated with biological therapies.
    Chinniah N; Cains GD
    Australas J Dermatol; 2014 May; 55(2):128-31. PubMed ID: 24456051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
    Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
    Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
    van Rappard DC; Leenarts MF; Meijerink-van 't Oost L; Mekkes JR
    J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.
    Gottlieb A; Natsis NE; Kerdel F; Forman S; Gonzalez E; Jimenez G; Hernandez L; Kaffenberger J; Guido G; Lucas K; Montes D; Gold M; Babcock C; Simard J
    J Invest Dermatol; 2020 Aug; 140(8):1538-1545.e2. PubMed ID: 32004568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
    Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
    [No Abstract]   [Full Text] [Related]  

  • 35. The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review.
    van Rappard DC; Limpens J; Mekkes JR
    J Dermatolog Treat; 2013 Oct; 24(5):392-404. PubMed ID: 22397574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.
    Moyano B; Clemente A; Marín-Jiménez I; Martorell A
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():43-50. PubMed ID: 28081769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa.
    Argyropoulou M; Trigoni A; Kaffenberger J; Stergianou D; Damoraki G; Mingiani E; Micha S; Krispinsky A; Meltzanidou P; Kanni T; Lazaridou E; Giamarellos-Bourboulis EJ
    Dermatology; 2023; 239(5):746-752. PubMed ID: 37331331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.
    Haslund P; Lee RA; Jemec GB
    Acta Derm Venereol; 2009 Nov; 89(6):595-600. PubMed ID: 19997689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa.
    Ricceri F; Rosi E; Di Cesare A; Pescitelli L; Fastame MT; Prignano F
    Dermatol Ther; 2020 Nov; 33(6):e14387. PubMed ID: 33030281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.
    Scheinfeld N; Sundaram M; Teixeira H; Gu Y; Okun M
    Dermatol Online J; 2016 Mar; 22(3):. PubMed ID: 27136622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.